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Abstract
Antibiobodies are paradigmatic of yeast killer toxin (KT)-like antibodies (KAbs)
mimicking the antimicrobial activity of KTs in the frame of the yeast killer
phenomenon. Polyclonal, monoclonal and recombinant anti-idiotypic antibio-
bodies (anti-idiotypic KAbs), internal images of a wide-spectrum KT produced by
the yeast Pichia anomala (PaKT), have been produced by immunization with the
idiotype of a PaKT-neutralizing monoclonal antibody. Anti-idiotypic KAbs
showed microbicidal activity against eukaryotic and prokaryotic pathogenic agents
through the interaction with specific KT receptors (KTRs), putatively constituted
by b-glucans. Natural KAbs have been found in animals and humans experimen-
tally or naturally infected by KTR-bearing microorganisms. Recombinant KAb-
derived synthetic killer peptides showed further antiviral and immunomodulatory
activities. The perspectives of KAbs and killer peptides as potential sources of novel
therapeutic agents, and of KTRs and idiotypes as vaccines against infectious
diseases are discussed.
Introduction
In the environment, microorganisms must resort to differ-
ent strategies to compete for limiting nutritional resources.
Secretion of killer toxins (KTs) represents an efficient tool to
eliminate competitors without direct cell-to-cell contact, a
property widely distributed among yeast species/genera.
KTs’ genetic determinants, physical-chemical properties
and mechanisms of recognizing and killing susceptible
strains are heterogeneous. Killer yeasts secrete protein or
glycoprotein KTs that generally kill susceptible cells in a two-
step receptor-mediated manner. First, KTs bind to primary
cell wall receptors (KTRs) and then translocate to the plasma
membrane where they interact with secondary KTRs or
enter susceptible cells, thus exerting their cytocidal effect
(for reviews, see Magliani et al., 1997a; Schmitt & Breinig,
2006).
Almost all the different fungal cell wall structural compo-
nents (Lesage & Bussey, 2006; Ruiz-Herrera et al., 2006) can
act as primary KTRs. Double-stranded mycoviral RNA-
encoded KTs in Saccharomyces cerevisiae bind to b-1,6-
glucan (K1 and K2) or a-1,3-linked mannose residues in
the mannoprotein layer (K28). Other KTs can interact with
b-1,6-glucan, such as Pichia membranifaciens (PM)KT and
FC-1 from Pichia membranifaciens (Santos et al., 2007) and
Filobasidium capsuligenum (Keszthelyi et al., 2006), respec-
tively. Zygocin from Zygosaccharomyces bailii (Weiler &
Schmitt, 2003) binds to an a-1,3-mannoprotein, while
chitin acts as a primary KTR of different heteromeric KTs
from Kluyveromyces lactis (zymocin), Pichia acaciae, Pichia
inositovora and Wingea robertsiae, among others (Jablo-
nowski & Schaffrath, 2007). b-1,3-Glucan has emerged as
the primary KTR/target of KTs produced by different Pichia
and Williopsis species.
The second, energy-dependent step involves KT translo-
cation to secondary membrane KTRs. Among them, few
have been identified so far, such as Kre1p, a glycosyl
phosphatidyl inositol (GPI)-anchored protein involved in
b-1,6-glucan synthesis, for K1 (Breinig et al., 2002); Cwp2p,
a mannoprotein that plays a role in stabilizing the cell wall
whose precursor is GPI-anchored to the plasma membrane,
for PMKT (Santos et al., 2007); and the four amino acid
hepitope HDEL receptor Erd2p, which colocalizes to the
cytoplasmic membrane, for K28 (Schmitt & Breinig, 2006).
Some KTs, such as K1, K2, zygocin and PMKT, rapidly kill
susceptible cells by forming cation-selective ion channels,
thus disrupting plasma membrane integrity and function.
Some others interfere with essential proteins that are
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involved in cell cycle control and/or chromosomal DNA
synthesis. Among them, K28 is taken up by endocytosis,
travels the secretion pathway in reverse to the endoplasmic
reticulum and acts in the nucleus by blocking DNA synthesis
and causing a cell cycle arrest at the G1/S boundary (Santos
& Marquina, 2004; Schmitt & Breinig, 2006). Other KTs can
arrest cell cycle. In plasmid-encoded heterotrimeric KTs,
after binding to chitin, the hydrophobic b-subunit allows
the subsequent import of the lethal g-subunit into the
susceptible cell. In zymocin and P. inositovora KT, this
subunit has been shown to be an anticodon nuclease. It
targets tRNAs, by causing their depletion, block in translation
and G1 cell cycle arrest that prevents cell budding (Jablo-
nowski & Schaffrath, 2007). Pichia acaciae and W. robertsiae
KT g-subunits lead to S-phase arrest and concomitant
activation of the intra-S-phase DNA damage checkpoint
(Klassen et al., 2004).
Lethal necrotic effects are observed in susceptible cells in
the presence of high concentrations of KTs. Under low-to-
moderate doses, as in natural habitats, KTs can induce an
apoptotic cell death, which is mediated by yeast caspase
Yca1p and is characterized by production of reactive
oxygen species, DNA fragmentation and phosphatidylserine
flipping to the outer layer of the membrane. Thus, apoptosis
could be a general KT-induced cell death mechanism
under natural environmental conditions (Schmitt & Reiter,
2008).
Killer yeasts are immune to their own KTs, while remain-
ing susceptible to others. Immunity usually appears to be
closely associated with the KT-encoding genetic elements
and its mechanism(s) remains one of the most intriguing
aspects of the killer phenomenon. As killer yeasts bear cell
wall KTRs and bind normal amounts of KT, membrane
KTRs or other still unknown cellular components appear to
be involved. In S. cerevisiae K1-producing strains, an inter-
action between Kre1p and the intracellular preprotoxin
(pptox) has been suggested to lead to diversion of the
complex from the secretory pathway to degradation in the
vacuole. Because K1 binds to the plasma membrane, im-
munity apparently does not involve loss of Kre1p but affects
a still unknown step downstream of K1 binding (Schmitt &
Reiter, 2008). K28-producing strains take up their own
secreted toxin and translocate it back to the cytosol, where
it can form a complex with the intracellular preprotoxin
molecules that have not yet been imported into the endo-
plasmic reticulum. The b-subunit in the complex is selec-
tively polyubiquitinated and rapidly degraded by the
proteasome, allowing KT-producing cells to inactivate the
toxin before the a-subunit reaches its ultimate intracellular
target. Thus, as also suggested in other killer systems such as
K. lactis and P. acaciae (Paluszynski et al., 2007), the most
frequently applied strategy for achieving immunity appears
to be disarming KTs at the intracellular stage.
Some KTs, such as K1 and K28, are characterized by a very
narrow spectrum of activity limited to susceptible strains of
the same species. Some others, such as chromosomally
encoded KTs produced by killer strains belonging to Pichia
andWilliopsis species, have attracted increasing attention for
their wide spectrum of activity, involving human, animal
and plant pathogenic microorganisms. Most of them inter-
fere with cell wall synthesis by recognizing b-glucans as a
KTR/target. Inhibition of b-glucan synthase activity is
the main effect of HM-1 and HYI, small KTs fromWilliopsis
saturnus var. mrakii IFO 0895 and var. saturnus IFO 0117,
respectively (Komiyama et al., 1996, 1998). A strong
b-1,3-glucanase activity is the primary killing mechanism
of KTs such as panomycocin from Pichia anomala NCYC
434 (Izgu¨ et al., 2007), WmKT from W. saturnus var. mrakii
MUCL 41968 (Guyard et al., 2002), KpKT from Kluyver-
omyces phaffii (Comitini et al., 2004) and a recently de-
scribed KT from a marine strain of P. anomala (Wang et al.,
2007).
A 105 kDa KT glycoprotein produced by P. anomala ATCC
96603 (PaKT), in particular, has been shown to display
peculiar properties. PaKT is characterized by a wide spectrum
of antimicrobial activity, inclusive of Candida albicans,
P. anomala, S. cerevisiae and Pneumocystis carinii (Magliani
et al., 1997a). Even though its mechanism of action is still
obscure, it appears to be mediated by direct interaction with
specific cell wall KTRs, putatively represented by b-glucans
(mainly b-1,3-glucan). Furthermore, PaKT appears to be
antigenically related to WmKT (Guyard et al., 2001). By
damaging the integrity of the vital b-glucan scaffold, these
KTs induce rapid cell death, by osmotic lysis, similar to that
observed with echinocandins (Morrison, 2006).
Research on killer systems has allowed clarification of
relevant aspects of eukaryotic cell biology, such as protein
intracellular processing, maturation and secretion, virus–
host cell interactions, fungal cell wall structure and synth-
esis. Killer yeasts and KTs have been exploited in the food
and fermentation industries as biocontrol agents (Lowes
et al., 2000), in recombinant DNA technology (Eiden-Plach
et al., 2004), and in biotyping of medically and industrially
important microorganisms (Buzzini et al., 2007), as well as
in the development of novel potential antimicrobial agents.
From this perspective, a direct use of KTs as potential
therapeutic agents has been discouraged by their character-
istics. With few exceptions, most KTs are heat-labile, pro-
tease-susceptible macromolecules, which display their
activity only within narrow pH and temperature ranges,
usually below physiological limits. They are characterized by
antigenicity and toxicity, as demonstrated for PaKT (Pet-
toello-Mantovani et al., 1995). To our knowledge, the
demonstration that topical application of concentrated
PaKT was curative against cutaneous experimental infec-
tions by Malassezia spp. in different animal models is the
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only reported evidence of the therapeutic effectiveness of a
KT (Polonelli et al., 1986).
The generation of immunological derivatives that mimic
the antimicrobial activity of KTs, on the basis of the
idiotypic network hypothesis, has been pursued. Antibio-
tic-like antibodies named ‘antibiobodies’ (Polonelli et al.,
1991) or killer antibodies (KAbs), i.e. antimicrobial anti-
bodies that bear the internal image of the active site of a
PaKT, have been generated.
From killer toxins to killer antibodies
The anti-idiotypic innovative approach was based on the
assumption that the interaction between a KT and specific
antibodies able to neutralize its activity could mirror the
interaction with its specific cell wall KTRs on susceptible
microorganisms. In an analogous way, anti-idiotypic and
anti-KTR KAbs could be functionally equivalent to the KT-
active site. An anti-PaKTmonoclonal antibody (mAb KT4)
has been produced by conventional fusion of splenocytes
frommice primed with PaKT, which proved to neutralize its
killer activity against a reference strain of C. albicans
(Polonelli & Morace, 1987). When mAb KT4 was used to
immunize rabbits by idiotypic vaccination, anti-idiotypic
KAbs were raised, which were able to compete with PaKT for
binding to mAb KT4 and, more importantly, to inhibit the
growth of the susceptible reference strain, thereby mimick-
ing the candidacidal activity of PaKT (Polonelli & Morace,
1988). Parenteral or intravaginal idiotypic vaccination with
mAb KT4 in mice or rats elicited serum or secretory anti-
idiotypic KAbs, which were candidacidal in vitro and
significantly protected animals against systemic or mucosal
candidiasis (Polonelli et al., 1993, 1994). The mucosal
inoculation of PaKT-susceptible C. albicans cells was able to
boost secretory KAbs in animals immunized previously with
mAb KT4 as well as to elicit the production of KAbs in naı¨ve
animals, thus demonstrating the functional equivalence
between the idiotype of mAb KT4 and PaKTR. Accordingly,
natural anti-PaKTR KAbs were also consistently found in
the vaginal fluid of women affected by vaginal candidiasis,
following natural exposition to the yeast KTRs (Polonelli
et al., 1996). Finally, these observations have been confirmed
by the production of anti-idiotypic KAbs in the monoclonal
(m-KAb) (mAb K10, IgM) and single-chain recombinant
(r-KAb) (scFv H6) format, from splenocytes of rats or mice
immunized with mAb KT4 (Magliani et al., 1997b; Polonelli
et al., 1997).
Irrespective of their origin, all these KT-like antibodies
display the same functional characteristics: they are able to
compete with PaKT for binding to mAb KT4 and PaKTRs,
exert a candidacidal activity in vitro on PaKT-susceptible
C. albicans cells and display a significant therapeutic activity
in experimental animal models of systemic and mucosal
candidiasis when passively transferred to normal and im-
munodeficient naı¨ve animals. Interestingly, their candidaci-
dal activity can be specifically neutralized by mAb KT4 and
laminarin, a soluble b-1,3-glucan from Laminaria digitata,
suggesting that b-glucans are involved, entirely or in part, in
the structure of the PaKTR. In addition, cell wall PaKTRs in
C. albicans can be easily visualized using KAbs in immuno-
fluorescence studies; they appear to be preferentially ex-
pressed on growing cells and particularly on budding cells
and germ tubes, where the cell wall is neo-synthesized and
b-1,3-glucans are temporarily exposed at the cell surface, as
shown in Fig. 1.
Even though the precise clinical relevance of these micro-
bicidal antibodies in disease remains to be elucidated, their
limitless availability and greater stability at different tem-
peratures and pH, as compared with PaKT, allowed their
testing in vitro against many different microbial eukaryotic
and prokaryotic pathogens and their use as therapeutic
agents in experimental animal models of infection. Besides
C. albicans, KAbs demonstrated a significant in vitro wide
spectrum of microbicidal activity against other yeast and
fungal species, such as Candida spp. (Manfredi et al., 2005),
P. carinii (Se´guy et al., 1997) and Aspergillus fumigatus
(Cenci et al., 2002) as well as pathogenic bacteria, such as
multidrug-resistantMycobacterium tuberculosis (Conti et al.,
1998), antibiotic-resistant Gram-positive cocci (Conti et al.,
2000), oral streptococci (Conti et al., 2002) and protozoa,
such as Leishmania major, Leishmania infantum (Savoia
et al., 2002), and Acanthamoeba castellanii (Fiori et al.,
2006). More importantly, KAbs exerted a significant ther-
apeutic effect in experimental models of candidiasis, asper-
gillosis and pneumocystosis. This anti-idiotypic approach
has been confirmed recently by further experimental
evidence. Mice were immunized with a mAb neutralizing
the candidacidal and b-1,3-glucan synthase inhibitory
activities of HM-1. By recombinant DNA technology and
Fig. 1. Immunofluorescence visualization of PaKTRs on Candida albi-
cans germinating cells with affinity chromatography purified PaKT-like
biotinylated mAb K10 and fluorescent streptavidin ( 1000).
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phage display, an anti-idiotypic r-KAb in the single-chain
format has been produced that mimics HM-1 by displaying
in vitro the same killing and inhibitory activities (Selvaku-
mar et al., 2006). The availability of genes encoding r-KAbs
could allow their easy genetic manipulation, such as cloning
and expression in human commensal bacteria for direct
production and delivery of therapeutic anti-idiotypic
r-KAbs at mucosal sites, as demonstrated in Streptococcus
gordonii (Beninati et al., 2000). Finally, sequencing of r-KAb
genes could enable the synthesis and selection of
potent antimicrobial antibody-derived peptides, opening
further, unexpected biotechnological and therapeutic new
perspectives.
From killer antibodies to killer peptides
More than 200 decapeptides that overlapped by two-residues
and reproduced the entire variable regions of scFv H6 and the
six peptides pertaining to its complementary determining
regions (CDRs) have been synthesized and tested in vitro
against the C. albicans reference strain. Among different
candidacidal peptides, one decapeptide (P6) was selected for
further studies because of its high activity. The final residues
of its sequence (EKVTMTCSAS) were the first three of the VL
CDR1. P6 alanine scanning analysis allowed the generation of
a killer decapeptide (KP, AKVTMTCSAS, MW 998.2), with
A replacing E, which showed a significant increase in candi-
dacidal activity (Polonelli et al., 2003). The peptide activity,
which appeared to be mediated by interaction with specific
yeast cell wall b-glucan KTRs, was strongly and dose-depen-
dently inhibited by laminarin. Moreover, the peptide com-
pletely inhibited the binding of KAbs to germinating
C. albicans cells. Thus, KP retained the same activity of the
r-KAb from which it was derived, demonstrating a rapid
candidacidal effect in time-killing studies, in comparisonwith
a scrambled control peptide named SP (MSTAVSKCAT),
synthesized on the basis of the KP sequence, which showed
no candidacidal activity (Magliani et al., 2004a, b).
These characteristics and the easy production and testing
of KP allowed the demonstration of its activity in vitro
against all the microbial pathogens previously shown to be
susceptible to KAbs, for example C. albicans (Magliani et al.,
2004b, 2007; Fiori et al., 2006; Savoia et al., 2006), but also
against new ones such as Cryptococcus neoformans (Cenci
et al., 2004), Paracoccidioides brasiliensis (Travassos et al.,
2004) and phytopathogenic bacteria (Pseudomonas syringae
and Erwinia carotovora) and fungi (Botrytis cinerea and
Fusarium oxysporum) (Donini et al., 2005). More impor-
tantly, KP proved to be therapeutic in normal and immu-
nocompromised animals in experimental infections, such as
vaginal and systemic candidiasis (Polonelli et al., 2003), as
well as disseminated cryptococcosis (Cenci et al., 2004) and
paracoccidioidomycosis (Travassos et al., 2004). Thus, KP
displayed a sufficient in vivo stability and its antimicrobial
activity was observed irrespective of mechanisms of resis-
tance to other conventional antimicrobial drugs and the
host’s response.
The antimicrobial mechanism(s) of action of KP is yet to be
identified. The screening of KP activity against a comprehen-
sive S. cerevisiae nonessential gene deletion collection (Euro-
scarf, Frankfurt, Germany) failed to detect any resistant mutant
derivative. This finding might suggest that a KP-resistant
phenotype is not compatible with viability (Conti et al.,
2008). As shown in Fig. 2, KP-treated C. albicans cells are
characterized by the appearance of significant internal altera-
tions, including cell wall swelling with a middle electron-dense
region, plasma membrane collapse, condensation and frag-
mentation of nuclear material, similar to what is observed in
cells treated with acetic acid, a classical apoptotic agent.
As a small molecule, KP can be easily manipulated and
tested for new additional activities. KP was expressed in
Nicotiana benthamiana, using a Potato virus X-derived
vector, yielding chimeric virus particles displaying an active
form of the peptide. KP-expressing plants showed enhanced
resistance to bacterial experimental infections (Donini et al.,
2005). KP demonstrated a selective binding to murine
Fig. 2. TEM showing the cytotoxic effects
of the KP on Candida albicans. Yeast cells were
treated with KP (left) or with a SP (right).
Major alterations can be seen as the swelling of
the cell wall with an electron-dense middle
layer, plasma membrane collapse, chromatin
condensation and nuclear fragmentation.
SP-treated cells were identical to control
untreated cells (not shown).
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dendritic cells (DCs) and to a lesser extent to macrophages,
thus modulating the expression of costimulatory and MHC
molecules and improving DC capacity to induce lympho-
cyte proliferation (Cenci et al., 2006). KP was found to
possess sequence homology with critical segments in gp160
V1/V2 and V3 loops of HIV-1 and was able to inhibit virus
replication in peripheral blood mononuclear cells (PBMCs)
either from patients in the acute phase of infection or
exogenously infected with R5 or X4 strains. Downregulation
of the CCR5 coreceptor and/or physical blockade of the
gp120-receptor interaction have been suggested as possible
mechanisms of KP activity. KP did not inhibit the in vitro
replication of other RNA and DNA viruses (Casoli et al.,
2006). Thus, KP appears to be the first anti-idiotypic anti-
body-derived peptide displaying inhibitory activity and
potential therapeutic effect against pathogenic microorgan-
isms and viruses by different mechanisms of action.
Conclusions
Even though many questions concerning the molecular
mechanisms of action and possible clinical applications of
KAbs and KAb-derived peptides are still unanswered, this
ongoing story of KTs and their immunological derivatives
suggests some intriguing considerations and perspectives.
(1) While excluding a direct use of KTs as therapeutic
agents, unravelling their mechanisms of action could
result in the discovery of new potential targets for
antimicrobial agents.
(2) Microbicidal antibodies can be elicited either during
infections by KTR-bearing pathogenic microorganisms
or following idiotypic vaccination with KT-neutralizing
antibodies. Other wide-spectrum microbicidal antibodies
directed to different cell targets have been described more
recently, such as Mycograb, mAb C7 and anti-b-glucan
antibodies, suggesting the existence of a family of micro-
bicidal antibodies whose clinical relevance still needs to
be determined (Magliani et al., 2005).
(3) Immunological derivatives of KTs in different formats
exhibit speciﬁc beneﬁts and limitations compared with
KTs, as described in Fig. 3. In particular, antibody-derived
peptides, such as KP, can retain themicrobicidal activity of
the whole antibody and display antimicrobial, antiviral
and immunomodulatory activities (Magliani et al., 2007).
(4) b-Glucans have emerged as viability-critical micro-
bial structures targeted by KAbs and KP, as well as by
Fig. 3. Potential and limits of PaKT and its immunological derivatives in different formats.
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antifungals. These carbohydrates are not biosynthesized
by mammalian cells, but they are produced by a wide
range of microbial species (Magliani et al., 2008). Their
relevance is also attested by the demonstration that
a b-glucan (laminarin)-conjugate vaccine was protective
against different fungal experimental infections, by elicit-
ing fungicidal antibodies (Torosantucci et al., 2005).
(5) Immunological derivatives of KTs, killer peptides in
particular, lack cytotoxicity, as demonstrated for KP on
PBMCs and in vitro-cultured cell lines (Magliani et al.,
2004a; Casoli et al., 2006).
Overall, KTs and KT-like molecules can represent proto-
typal compounds for the development of new receptor-
driven drugs for antimicrobial and antiviral therapy, even in
combination with current anti-infective agents. On the
other hand, KTRs and some idiotypes might represent
candidate vaccines for immunoprevention of infections
through an unconventional mechanism, such as the elicita-
tion of antibodies with direct antimicrobial activity. Thus,
new exciting perspectives could be opened in the field of
human, animal and even plant infectious diseases, where
antimicrobial and antiviral resistance is spreading among
relevant pathogenic agents and new less susceptible/resistant
species are emerging (Magliani et al., 2002, 2003).
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